Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

NCT03328078 is registered in ClinicalTrials.gov with Curis, Inc. as lead sponsor.

NCT NCT03328078
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03328078 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
Lead sponsor
Curis, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 28, 2017
Completion date
October 31, 2027
Enrollment
152 (estimated)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

refractory hematologic malignancy, refractory primary central nervous system lymphoma, relapsed hematologic malignancy, relapsed primary central nervous system lymphoma